Allogene Therapeutics, Inc. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Allogene Therapeutics, Inc. (ALLO) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $2.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-12
- Allogene Therapeutics, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $2.21M, a 29.33% decline from fiscal 2024.
- Allogene Therapeutics, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $3.12M, a 27.86% decline from fiscal 2023.
- Allogene Therapeutics, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $4.33M, a 9.37% decline from fiscal 2022.
- Allogene Therapeutics, Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $4.77M, a 31.21% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 1 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|---|
| 2025-12-31 | $2.21M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $3.12M 10-K · filed 2026-03-12 | |
| 2023-12-31 | $4.33M 10-K · filed 2025-03-13 | |
| 2022-12-31 | $4.77M 10-K/A · filed 2024-03-14 | |
| 2021-12-31 | $3.64M 10-K/A · filed 2024-03-14 | |
| 2020-12-31 | $3.01M 10-K/A · filed 2024-03-14 | |
| 2019-12-31 | $2.23M 10-K · filed 2022-02-23 | |
| 2018-12-31 | $920.00K 10-K · filed 2021-02-25 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |